Seven mouse monoclonal antibodies (IgGs) were produced against rat neurophysins (NPs). Three were specifically directed against vasopressin-associated NP (NP-AVP), and four were specific for oxytocinassociated NP (NP-OT).
Abstract
Seven mouse monoclonal antibodies (IgGs) were produced against rat neurophysins (NPs). Three were specifically directed against vasopressin-associated NP (NP-AVP), and four were specific for oxytocinassociated NP (NP-OT).
These specificities were observed in liquid phase assays, immunoblot, and immunoprecipitation experiments. Homozygous Brattleboro rat tissues and extracts, which do not contain vasopressin or NP-AVP, did not react with the anti-NP-AVP antibodies but reacted with high affinity to the anti-NP-OT antibodies.
In immunoprecipitation assays the antibodies brought down the appropriate NPs as well as their precursor molecules synthesized in vivo with no detectable cross-reactivity. In solid phase assays where the antigens were presented in a different manner, there was a significant cross-reactivity of the anti-NP-AVP antibodies with NP-OT. The extent of this cross-reactivity in solid phase correlated with the cross-reactivities of the antibodies observed in immunocytochemical studies. These solid phase (and immunocytochemical) data demonstrated that liquid phase specificities and absorption controls of antibodies are inadequate to assess their immunocytochemical (solid phase) specificities. Posterior pituitary extracts from the mouse and frog, as well as purified NPs from the rat, cow, and human were studied for their cross-reactivities to two of the antibodies, PS 36 and PS 45. In liquid phase assays the anti-rat NP-OT antibody, PS 36, reacted only with rat and mouse NPs and did not cross-react with NPs from any of the other species. In contrast, the anti-rat NP-AVP antibody, PS 45, was cross-reactive across species lines including an NP-like antigen extracted from frog posterior pituitaries.
Immunoblot staining with these antibodies showed heterogeneity of NP-AVP and NP-OT in the rat posterior pituitary. Analysis of the epitopes for PS 36 and PS 45 indicated the antigenic determinants were located near amino acid positions 80 to 81 in NP-OT and 75 to 86 in NP-AVP, respectively.
The neurophysins (NPs) are acidic proteins of M, = 10,000, which are invariantly found associated with the neuropeptide hormones, oxytocin (OT) and vasopressin (AVP), in the hy- pothalamo-neurohypophysial system (Pickering and Jones, 1978; Seif and Robinson, 1978; Breslow, 1979; Cohen et al., 1979; Chaiken et al., 1983) . They represent a family of highly homologous, disulfide-rich proteins, and specific NPs are associated with either AVP or OT in equimolar amounts in each neurosecretory (granulated) vesicle (NSV).
Their principal function appears to be to act as "carrier" proteins for the peptide hormones, which they bind intravesicularly in a noncovalent complex. Upon secretion from nerve terminals in the posterior pituitary, they are co-released with the peptide hormones (Seif and Robinson, 1978) . This intimate relationship between the NPs and the neuropeptides begins with the biosynthesis of the hormones. Vasopressin and the vasopressinassociated neurophysin (NP-AVP), and oxytocin and the oxytocin-associated neurophysin (NP-OT) are synthesized in separate neurons in the hypothalamus as part of common (prohormone) precursors (Brownstein et al., 1980; Ivell et al., 1983; Gainer, 1983) . Because the neurons of the hypothalamo-neurohypophysial system are the best understood peptidergic neu-rons in the central nervous system, we were motivated to produce monoclonal antibodies to various molecular components (e.g., the NPs) in this system, in order to use these immunological "reagents" in a variety of cell biological studies. Monoclonal antibodies are powerful tools for neurobiological studies (Barnstable, 1980; Zipser and McKay, 1981) and have many advantages, but also limitations (Edwards, 1981; Yelton and Scharff, 1981) . The advantages allow for the production of homogeneous, reliable, and unlimited amounts of defined antibody reagents which can be used in both biochemical and morphological experiments.
One of the limitations we were particularly concerned with was that, because of its homogeneity, a monoclonal antibody may not be able to distinguish between different molecules that bear similar antigenic determinants (see Edwards, 1981) . Considerable confusion has surfaced in the neurobiological literature because of such crossreactivities.
For this reason, we have focused in this paper on the cross-reactivities of the monoclonal antibodies that we have produced. Antisera (polyclonal antibodies) against specific rat NPs have been produced, and these have shown low crossreactivities in liquid phase radioimmunoassays (RIAs) (McPherson and Pickering, 1978; North et al., 1983) . However, their use in solid phase assays and immunocytochemistry has not been reported, and it is possible that when they are evaluated in such assays their cross-reactivities will be unacceptable. Because of their polyclonal nature, it is difficult to evaluate the basis of the cross-reactivity in antisera, especially in solid phase assays such as immunocytochemistry.
In this paper we describe the production of seven mouse monoclonal antibodies reacting with rat NP and characterize their cross-reactivities by several types of biochemical and immunocytochemical assays. We were particularly interested in producing antibodies which would react with NP-OT and its precursor protein, but which would not cross-react with NP-AVP and its precursor. In the accompanying paper (Whitnall et al., 1985) , a morphological study of the ontogeny of this neuronal system, based on the use of such characterized antibodies, is presented. and Milstein, 1975; Gefter et al., 1977; Kennett et al., 1980; Ozato et al., 1980; 1981 was performed on 11% acrylamide slab gels by conventional methods (Laemmli, 1970) , and isoelectric focusing was done in 7.5% polyacrylamide gels as described previously (Russell et al., 1980) . Ampholytes (Bio-Rad) used were in the pH ranges 4 to 6 and 3 to 10 in a ratio of 9:1, respectively. 
Materials and Methods

Preparation
Results
In one of several fusion experiments, of a total of 1620 wells plated, 1319 wells (82%) showed significant cell growth 10 to 14 days after the fusion. Initial screening of the media from wells containing cell growth, by ELISA performed with acidsoluble posterior pituitary peptides as antigens, showed that 72 wells (5.5%) were above background in this assay (data not illustrated).
The media from these positive wells were then screened by immunohistochemical staining of pituitary and brain sections (see "Materials and Methods"). Two major staining patterns were observed: media from 56 of the screened wells contained antibodies which stained glial and neuronal intracellular elements in the whole pituitary gland as well as in all brain areas, whereas media from 16 wells exclusively stained the posterior pituitary, the paraventricular nuclei (PVNs), and the SONS. An example of such staining from one of the 16 wells is shown in Figure 1 . Of the 16 wells whose supernatants showed specificity for the hypothalamo-neurohypophysial system, we were able, following limiting dilution cloning, to establish and expand seven stable clones (Table I) .
Identification of the antigens recognized by the monoclonul antibodies. In order to elucidate the identity of the antigen(s) recognized by the antibodies, we first determined the molecular weights of the antigen(s) by immunostaining SDS-PAGE transblots of the posterior pituitary soluble extract. Figure 2 illustrates that all of the antibodies stained a band of about nli, = 10,000 which co-migrated with NP, a major protein found in this system. We next performed RIAs with these monoclonal antibodies on microtiter plates in which the wells had been coated with affinity-purified NPs from normal rats. These data are illustrated in Figure 3 . All of the PS monoclonal antibodies bound to the affinity-labeled NPs, whereas the control monoclonal antibodies (30-5-7 and 4-9-11, directed against mouse histocompatibility antigens, Ozato et al., 1980) did not significantly differ in binding from the HAT medium control. Although the above solid phase immunoassays (Figs. 2 and 3) are valuable for rapid and simple evaluations of antibody specificity, a more precise and quantitative determination would be to use liquid phase RIAs (Berzofsky and Schechter, 1981) . Figure 4 depicts such an analysis for two of the monoclonal antibodies (PS 36 and PS 45) in which '251-NP (from normal rats) was used as the tracer. The data in this figure show that unlabeled NP was highly effective in displacing the 1251-NP from the PS 36 (Fig. 4A ) and PS 45 (Fig. 4B) anti- In contrast, the highly abundant peptide hormones, AVP and OT, had little or no inhibitory effects on either antibody's ability to bind NP at concentrations as high as 10,000 pmol/tube. Other peptides which are known to be found in the rat neurointermediate lobe, i.e., dynorphin A and dynorphin B (100 pmol/tube), @-endorphin (100 pmol/tube), ol-melanocyte-stimulating hormone (01-MSH, 1000 pmol/tube), and angiotensin II (10,000 pmol/tube), also did not affect antibody binding (data shown only for angiotensin II in Fig. 4 ). These data demonstrate that PS 36 and PS 45 are specific for NP. Even in the case of PS 45, where AVP and OT caused tracer displacement at high concentrations, the efficacy of NP relative to these peptides to produce 50% inhibition of binding was larger than 10,OOO:l. Similar experiments were done using the other PS monoclonal antibodies, with similar results (not illustrated).
The affinity constants of the various antibodies for rat NP, derived from such displacement curves, are presented in Table I . Specificities and cross-reactiuities of the antibodies for the two NPs. The hypothalamo-neurohypophysial system of normal rats contains two distinct NPs, one associated with the cells that synthesize and secrete AVP (i.e., NP-AVP), and the other found in cells that produce OT (i.e., NP-OT).
In the experiments described above (Figs. 2 to 4) , no effort was made to distinguish between these two NPs. In the experiments to be described below, the specificities of the monoclonal antibodies for each type of NP were determined.
Affinity-purified NP from posterior pituitaries of normal rats was used as a source of both NP-AVP and NP-OT, whereas pure NP-OT was obtained from posterior pituitaries of homozygous (DI/DI) Brattleboro rats which do not contain either AVP or NP-AVP (Sokol and Valtin, 1982) . Each of these NP Inhibitor Concentration(pmole) preparations (5 pg each) was iodinated (see "Materials and Methods").
In these assays, varying concentrations of culture supernatants were incubated with fixed amounts of the labeled NP preparations, and the antibody-antigen complexes were precipitated (see "Materials and Methods") and counted. The results of these experiments are shown in Figure 5 . The data indicate that the antibody specificities correspond to two groups. The first group includes PS 36, 38, 60, and 67, which precipitated only about 30% of the labeled normal NP but about 80% of the labeled NP-OT (from DI/DI rats) preparation. In contrast, the second group, which included PS 41, 45, and 46, completely failed to bind the DI/DI NP-OT even at the highest concentrations used, but reacted significantly with labeled NP from normal animals (40% bound by PS 45, which appeared to reach saturation levels). These experiments indicate that PS 41,45, and 46 are highly specific for NP-AVP and do not cross-react with NP-OT, whereas PS 36, 38, 60, and 67 react with NP-OT exclusively. These conclusions are strongly supported by displacement experiments in which unlabeled NP-OT completely inhibited the binding of normal labeled NP by PS 36, 38, 60, and 67 but did not affect binding by PS 41, 45, and 46, even at concentrations of 2500 rig/tube (data not shown). Figure 6C shows that when PS 36 and PS 45 are used together, at saturating concentrations (i.e., at the 10" dilutions shown in Fig. 5) , 100% of the immunoprecipitable normal ratlabeled NP can be bound. Either of these monoclonal antibodies used alone can only bind about 50% of the total immunoprecipitable label (Fig. 6, A and B) , which suggests that each of these antibodies recognizes a separate specific NP in the normal rat NP population.
Similar data were obtained when PS 38, 60, or 67 were mixed with PS 45 (not illustrated).
In contrast, mixtures of the anti-NP-OT antibodies (Fig. 6B ) and anti-NP- AVP antibodies (Fig. 6A ) did not bind greater than 50% of the total labeled NP. The fact that PS 41 and PS 46 bound less labeled NP than did PS 45 (Fig. 6A ) may be due, in part, to the lower titers of these antibodies in the supernatants (see counts per minute at 10" dilutions in Fig. 5 ). It is, however, apparent from the mix experiments in Figure 6A that the addition of PS 41 or PS 46 to PS 45 does not bind more NP label than do saturating levels of PS 45 alone.
The data in Figure 5 indicate that the anti-NP-AVP monoclonals do not cross-react with NP-OT, and the data in Figure  6 suggest a lack of cross-reactivity of the anti-NP-OT mono- Further evidence for the latter view is shown in Figure 7 . In this experiment, putative '251-NP-AVP was isolated from the labeled normal rat NP by immunoprecipitation with PS 45 (see "Materials and Methods"). The PS 45-bound NP was eluted with 0.1 N HCl, neutralized, and then used as substrate for experiments in Figure 7 . The data in Figure 7 show that this immunopurified iz51-NP-AVP can be fully bound by PS 45. However, none of the anti-NP-OT antibodies (PS 36, 38, 60, 67) could bind this tracer (Fig. 7 , solid circles), whereas all were fully capable of binding 1251-NP-OT (Fig. 7, open circles) . The conclusions of these studies are et al. Vol. 5, No. 1, Jan. 1985 lmmunoprecipitation of '*'I-Neurophysins (Np-AVP+Np-OT) Figure 6 . Immunoprecipitation of normal lz51-rat NP (containing both labeled NP-OT and NPIAVP) by kdividual and mixed antibody supernatants. Concentrations of antibodies used correspond to the 10" dilutions shown in Figure 5 . Note that the anti-NP-AVP (A) and anti-NP-OT (B) used alone or in pairs immunoprecipitated only around 50% of the total labeled NP, whereas the mixed antibodies (PS 36 and 45 in C) precipitated nearly 100%. The ordinate represents percentage of the total counts per minute in the incubate. N = 6 each, + SD. Cross-reactivities of the monoclonal antibodies in solid phase assays. Although the liquid phase assays described above are the methods of choice for cross-reactivity studies (see Berzofsky and Schechter, 1981; Berzofsky and Berkower, 1984) , neurobiological studies often employ solid phase assays. Since immunological reagents (such as monoclonal antibodies) are often evaluated for their specificities under liquid phase assay conditions but are used in biological studies under solid phase conditions (e.g., immunocytochemistry), we show the data in Figure 8 as a cautionary point in this regard. Although PS 41, 45, and 46 showed absolutely no cross-reactivity for NP-OT in the above liquid phase assays (Figs. 5 to 7), significant crossreactivity was observed with these antibodies to NP-OT from homozygous Brattleboro rats in solid phase assays (Fig. 8 , open circles). Note that while the measurable cross-reactivities for PS 41 and PS 46 could be "diluted out" (Fig. 8, A and C) , this was not possible for PS 45 (Fig. 8B) . Similar data were obtained when purified rat NP antigens were used to coat the wells (data not shown).
Cross-reactiuities of the monoclonal antibodies in immunocytochemistry. Several features of the morphology of the hypothalamo-neurohypophysial system of the rat served to facilitate our analysis of the antibody specificities to the NPs. These included the following.
(1) The PVN is organized into discrete subnuclei, some areas consisting of nearly all OT-containing or nearly all AVP-containing magnocellular neurons (Vandesande and Dierickx, 1975; Hatton et al., 1976; Armstrong et al., 1980; Swanson and Kuypers, 1980; Rhodes et al., 1981; Sofroniew and Glasman, 1981; Silverman and Zimmerman, 1983; Swanson and Sawchenko, 1983) . (2) Figure 9 illustrates the staining of these nuclei using three representative anti-NP antibodies, i.e., PS 36, 41, and 45. Figure 9A shows the staining pattern for an anti-NP-OT monoclonal antibody (i.e., PS 36): the ACN and SON stained intensely, whereas the SCN remained unstained. This indicates that the PS 36 antibody showed little if any cross-reactivity with NP-AVP in these immunocytochemical experiments. Similar results were obtained with the other anti-NP-OT antibodies, PS 38, 60, and 67 (data not shown). The anti-NP-AVP antibody PS 41 clearly stained both the SON and the SCN but also slightly stained some cells in the ACN (Fig. 9B) , indicating some cross-reactivity with NP-OT. A similar result was obtained using PS 46 (not illustrated).
This result with PS 41 was similar to that found in the solid phase assays (Fig. 8A) ; i.e., PS 41 is cross-reactive with NP-OT at high concentrations of antibody (or antigen, in the case of immunocytochemistry in Fig. 9B ). That the behaviors of the antibodies in the solid phase biochemical assay are relevant to their behavior in immunocytochemistry is confirmed by the observations using PS 45 (Fig. 9C) . PS 45 stained all of the nuclei (i.e., both OT and AVP neurons) very intensely (Fig. 9C ), indicating strong crossreactivity to NP-OT in the solid phase (see also Fig. 8C ). As in the case of the biochemical assay (Fig. 8C) , the cross-reactivity of PS 45 in immunocytochemistry could not be eliminated by dilution of the antibody (data not shown).
Immunocytochemical studies with the above three antibodies on the ultrastructural level were also performed. These studies represent an independent immunocytochemical test of antibody specificity since it is known that NP-AVPand NP-OT-containing vesicles are located in separate endings in the posterior pituitary (see Morris et al., 1978; Caste1 et al., 1984) . When ultrathin LR White sections of the posterior pituitary were stained with the anti-NP monoclonal antibodies, staining was present only over NSVs of about 160 nm in diameter which were located in subpopulations of axons, Herring bodies (swellings), and terminals (Fig. 10) . Serial sections stained with either PS 36 (Fig. 1OA ) or PS 41 (Fig. 1OB) showed staining in mutually exclusive populations of axons, swellings, and terminals, although PS 41 did display some cross-reactivity with the NSVs stained by PS 36. The reverse cross-reactivity, however, was not observed. All NSVs were stained by PS 45 (Fig. lOC) , and no dilution of this antibody could be found at which one subpopulation of axons stained more intensely than the other. The staining of all axons dropped out between 1:lOOO and 1:5000 (not shown). When mixtures of PS 36 and PS 41 were used, all of the NSVs stained in a manner similar to that shown for PS 45 in Figure 1OC (data not shown) . The control antibodies used at 1:lO dilutions resulted in no staining of the NSVs (Fig. 100) .
These immunocytochemical studies at both the light and electron microscopic levels indicate that antibody cross-reactivities in immunocytochemistry are better reflected by solid phase biochemical assays (as in Fig. 8 ) as opposed to liquid phase biochemical assays (as in Figs. 4 to 7) . Cross-reactiuities of PS 36 and PS 45 with phylogenetically diverse NPs. Several properties of the anti NP-OT PS 36 and anti NP-AVP PS 45 antibodies were favorable for an evaluation of the epitopes which they recognized on rat NP. These included their high specificities in liquid phase assays (Figs. 4 to 7) and their relatively high affinity constants (Table I ). In addition, the amino acid sequences of a variety of mammalian NPs are known (Pickering and Jones, 1978; Chauvet et al., 1981 Chauvet et al., , 1983 . By studying the cross-reactivities of these antibodies with phylogenetically diverse NPs of known structure, it was possible to correlate the antibody reactivity with the variations in NP amino acid sequence (see Table II and "Discussion"). Figure 11 illustrates liquid phase RIA data using PS 36 (Fig.  11A ) and PS 45 (Fig. 11B) and phylogenetically diverse sources of the NPs. The abscissa in Figure 11 is expressed in nanograms of unlabeled protein per tube. In this RIA the competitive displacements of Y-labeled rat NP (containing both 'Y-NP-AVP and iz51-NP-OT) by purified rat, bovine, and human NPs, as well as mouse and frog pituitary extracts, were compared. A qualitative analysis of the data in Figure 11A shows that PS 36 is quite reactive with rat and mouse NPs but does not appear to appreciably react with frog NP, cow NPI (cow NP-OT), or human NPIII (human NP-OT, or ESN) under these liquid phase conditions. It is possible that if higher concentrations (>l pg/ml) of inhibitors were used in these studies, some crossreactivity of PS 36 with frog, cow, or human NP would have Ben-Barak et al. Vol. 5, No. 1, Jan. 1985 Bar, 500 pm.
been observed. In contrast, PS 45 is much more generally crossreactive (Fig. 11B) . The order of strength of reactivity of PS 45 with various NPs was rat NP E mouse NP > cow NPII (cow NP-AVP) > human NPII, IV (two variants of NSN, human NP-AVP) E frog NP > cow NPI (NP-OT) > human NPIII (human NP-OT, ESN). From the above, it can be seen that the PS 45 cross-reactivity is generally greater for NPAVPs from other species as compared to NP-OTs, and, therefore, this antibody detects a conserved epitope which may be common to NP-AVPs across species lines. The apparent (but low) cross-reactivities of the NP-OTs from cows (cow NPI) and humans (human NPIII) may be, in part, due to a 10% contamination with NP-AVP molecules (see "Materials and Methods"). In this regard, it is interesting that the frog and pituitary extract cross-reacted with PS 45 (see "Discussion").
Heterogeneity of rat NPs. Isoelectric focusing of rat posterior pituitary extracts or affinity-purified rat NP reveals two major forms of NP: NP-OT, with a p1 of 4.6, and NP-AVP, with a p1 of 4.8 (Brownstein and Gainer, 1977; Russell et al., 1980) . When such isoelectric focusing gels were electroblotted onto nitrocellulose paper and stained by PS 45 or PS 36 antibodies, many immunoreactive bands were revealed (Figs. 12 and 13) . Figure 12 shows such immunostaining patterns for posterior pituitary extracts from homozygous (HOBB, DI/DI) and heterozygous (HEBB, DI/DI) Brattleboro rats. Although PS 45 fails to stain the HOBB pituitary extract (which does not contain NP-AVP), it stains considerably more than one band in the HEBB pituitary extract (which does contain NP-AVP). Thus, there appear to be several other forms of immunoreactive NP-AVP in HEBB rat pituitaries. This heterogeneity could be due to a slow proteolytic breakdown of the major form of NP-AVP during its long-term (>2 weeks) storage in the NSVs in the neural lobe. Similarly, the NP-OT, stained in both HOBB and HEBB extracts by PS 36, shows heterogeneity. It is of interest to note that at the dilutions of PS 45 used in this immunostaining of nitrocellulose blots, very little if any crossreactivity of PS 45 for NP-OT (HOBB) could be detected. Figure 13 shows immunoblot staining of affinity-purified normal rat NP (containing NP-AVP and NP-OT) by all of the monoclonal antibodies described in this paper. Although the high degree of heterogeneity in the stains using anti-NP-OT antibodies obscured their detailed patterns, it is clear that the major NP bands stained by the two classes of antibodies (Fig.  13 , large arrows) are different and are consistent with previous observations that the major form of NP-AVP is more basic than the major form of NP-OT (Brownstein and Gainer, 1977) .
The momclonul antibodies react with the NP precursors. It was of importance to establish whether the anti-NP antibodies could recognize the NPs in their precursor forms, i.e., in the Pro-PP and Pro-OP prohormones (Russell et al., 1980) . It was possible that the altered conformational structure of the precursor molecule might affect the specificity of the antibodies or render the antigenic determinant on the NPs inaccessible. In order to examine this question, radioactively labeled NPs and precursors were made by in uiuo biosynthesis in rats (see "Materials and Methods") and isolated. The 35S-labeled NP-AVP and NP-OT molecules synthesized in the SONS of living rats and transported to the posterior pituitary were then assayed for their reactivities to the antibodies by immunoprecipitation procedures. The data in Figure 14 show that these NPs synthesized in uiuo, yielded the same specificity patterns as the iodinated NPs studied earlier (i.e., in Figs. 5 to 7) . Figure 15 shows the results of a similar set of immunoprecipitation experiments using 3H-labeled NP precursors. The precursor containing NP-AVP, Pro-PP (Fig. 15A) , was recognized by PS 41,45, and 46, but not significantly by the anti-NP-OT antibodies (i.e., PS 38, 36, 60, and 67). The small apparent reactivity of the Pro-PP with the anti-NP-OT antibodies (compared to the HO-13-14 control) was probably due to the 10% contamination of the Pro-PP preparation by Pro-OP. In the case of the NP-OT precursor, Pro-OP (Fig. 15B) , each of the anti-NP-OT antibodies could immunoprecipitate the Pro-OP, whereas the anti-NP-AVP antibodies were completely ineffective. Thus, all of the antibodies recognized their respective NPs in precursor form. Whereas the anti-NP-OT antibodies appear to be equally effective in precipitating NP-OT or Pro-OP (Figs.  6,14, and 15) , the effectiveness of the anti-NP-AVP antibodies differed, in the order PS 45 >> PS 46 > PS 41 (Figs. 6, 14, and 15) . This is principally due to the lower apparent titers of the PS 41 and PS 46 antibodies in the culture supernatants (Fig.  5) , and the lower affinity constants of these two antibodies (Table I) . However, despite the lower effectiveness of the PS 41 and PS 46 antibodies in liquid phase assays (Fig. 6, 14 , and 15), they appear to be comparable in effectiveness to PS 45 in solid phase assays (Fig. 8 ) but with lower cross-reactivities.
Discussion
In this paper we have described the production and characterization of seven mouse monoclonal antibodies against rat NP. Three were directed specifically against NP-AVP (PS 41, 45, and 46), and four were specifically against NP-OT (PS 36, 33, 60, and 67). The antibodies also recognized the antigens (NP) in their precursor forms with few, if any, changes in selectivity, indicating that the antigenic sites in the NPs were still accessible in the prohormones (Pro-OP and Pro-PP; Fig.  15 ). Although these antibodies fall into two classes with respect to the rat NPs, (i.e., anti-NP-AVP and anti-NP-OT), crossreactivity studies using phylogenetically diverse NPs show that their antigenic determinants are not necessarily identical, even within classes. Only one of the antibodies (PS 67) was specifically directed against rat NP, whereas the others could react to varying degrees with NPs from other animal species ( Fig. 11 ; unpublished data). An unexpected result of this study was that even though our immunogen contained, in addition to NP, equimolar concentrations of AVP, OT, and the Pro-PP-derived glycopeptide, as well as substantial concentrations of ,&endorphin, (Y-MSH, dynorphin, and leucine-enkephalin, we obtained monoclonal antibodies only to NP. We have no explanation for this apparent relative efficacy of NP as an immunogen.
This could be related to a combination of factors: the relatively high concentration of NP in posterior pituitary extracts, its higher molecular weight (about 10,000) than the other peptides, and our KLH-coupling procedure. In a recent report, where mice were immunized with homogenized hypothalami (not using the KLH-coupling procedure), no monoclonal antibodies were obtained which were specifically directed against hypothalamic cells, although many "neuron-specific" antibodies were generated (Sternberger et al., 1982) . In addition to the nature of our immunogen and the KLH-coupling procedure, our initial screening strategy, which employed both ELISA assays and immunohistochemistry, was helpful in defining which hybridoma supernatants contained antibodies specific against the hypothalamo-neurohypophysial system. The use of glutaraldehyde in the KLH-coupling procedure enhanced the probability that any specific antibodies which would be generated would be useful in electron microscopic immunocytochemical experiments (Whitnall et al., 1983) where glutaraldehyde would be the fixative of choice.
Epitope analysis based on NP amino acid sequences and antibody cross-reactivities.
The cross-reactivity data shown in Figure 11 and the amino acid sequence variations in NPs shown in Table II permit a preliminary analysis of the epitopes recognized by PS 36 and PS 45. Figure 11 shows that: (a) PS 36 is relatively selective for rat (rodent) NP-OT as opposed to cow and human NP-OT (Fig. llA) , and (b) PS 45 appears to react with all NP-AVPs with varying affinities (Fig. 11B) . In addition, no cross-reactivity was observed between PS 45 and PS 36 with rat NP-OT and NP-AVP, respectively, in liquid phase RIA. iz51-NP from normal -rats (containing both lz51-NP-AVP and iz51-NP-OT) was used as the tracer in these experiments.
See "Materials and Methods"
and the text for description of the procedures. The abscissa shows the amount of specific purified NP (in nanograms) which was used as the inhibitor.
In the case of the mouse and frog pituitary extracts the nanogram value represents the amount of tissue protein used.
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PS 36, for example, should be interacting at amino acid sites which differ between rat NP-OT and rat NP-AVP, but also where differences exist between rat NP-OT and cow and human NP-OT. These sites of difference are shown by rectangles in Table II .
We believe that position 80-81 is the most likely epitope locus for PS 36. The reasons are as follows: (I ) the difference between all of the NP-AVPs and NP-OTs are most extreme in this position; i.e., position 80 contains a basic amino acid (Arg or His) in all NP-OTs as opposed to a hydrophobic amino acid (Val) in all NP-AVPs;
(2) reductive alkylation of rat NP-OT blocks all of its reactivity with PS 36 (unpublished data), suggesting that a nearby cysteine is involved (e.g., position 79); and (3) trypsin cleavage of the rat NP-OT does not eliminate its reactivity with PS 36 (Table III) , discounting positions 1 to 9 as participating in the epitope (Table II) . A similar analysis for the PS 45 antibody suggests that the amino acid positions 75 to 86 in rat NP-AVP contains the epitope. In this case, the cross-reactivity data imply some similarity between rat NP-AVP and cow and human NP-AVP, but differences between rat NP-AVP and rat NP-OT. The strong homologies in the central cores of NPs in general and the large differences between rat NP-AVP and cow NP-AVP from positions 89 to 95 remove these regions from consideration. This leaves the N-terminus, l-9, and the C-terminus, 75-88 (Table II) , as candidates. Similar experiments using trypsin cleavage (Table III) The anode was at the top in these focusing runs. Dilution of culture supernatant used for staining was 10-r (see Fig. 5 ), and total protein electrophoresed was 50 pg in each case.
to 89 positions as candidates (see Table II for tryptic cleavage sites), and the inhibition of reactivity by alkylation also suggests a nearby cysteine (e.g., cysteine 10 or cysteine 79). Position 9 in NP-AVP could be involved since all NP-AVPs have a Gln in this position in contrast to NP-OTs, which do not (see Table II ). Since the trypsin experiments in Table III exclude positions 1 to 8 in NP-AVP, then the epitope would have to extend from position 9 into the central core. However, this whole region (i.e., positions 9 to 28) is invariant between rat, cow, and human NP-AVPs, and such an epitope locus could not explain the variations in cross-reactivities found for PS 45 and these NP-AVPs (Fig. 11) . Hence, we believe that position 75 to 86 in NP-AVP is the most likely candidate for the epitope locus for PS 45. This locus would be near enough to the Ala-80 in rat NP-AVP to encompass the only change in cow and human NP-AVP (i.e., the change from Ala to Thr in position 81). This change would be consistent with the lower affinities of cow NP-AVP and human NP-AVP to PS 45 as compared to rat NP-AVP. Thus, it is most likely that PS 45 is recognizing rat NP-AVP near positions 75 to 86, centering on positions 79 to 81.
The above analysis cannot discount the possibility that the tertiary structure of NP may play a role in determining the epitope. Indeed, the complete loss of cross-reactivity after reductive alkylation of the cysteines in the NPs might suggest that this is the case. However, the gel electrophoresis-immunoblot studies were also done under reducing conditions and thereby produced abnormal folding of the molecules. Immunoreactivity was preserved under these conditions, suggesting that permanent modification of the cysteines (by alkylation) was necessary to prevent immunoreactivity with the antibodies.
Given the above caveats about this epitope analysis, we note that the 75 to 88 region represents a highly conserved amino acid sequence in the rat, cow, and human NP-AVPs (only two relatively conservative amino acid changes are made out of 14; Table II ). Not only are the amino acid sequences in this region conserved, but the codons for these amino acids are as well. Among the 42 nucleotides coding for the amino acids in this region, only four differences are found between the rat and the cow (Schmale et al., 1983) . In contrast, the codon changes between cow NP-OT and NP-AVP in this region involve 25 of the 42 nucleotides (Land et al., 1983) . Thus, the 75 to 88 region appears to be highly conserved in NP-AVPs between mammalian species but is very divergent from NP-OT even in the same species. This contrasts from the central core of NP (positions 10 to 74), which is highly conserved in all forms of NP. Hence, the 75 to 88 region of the NP-AVP (and NP precursor) must have evolved independently of the central core, and it is intriguing that the antibody which recognizes this epitope (i.e., PS 45) is able to cross-react with an antigen (presumably NP) extracted from frog posterior pituitaries (Fig. 11B ).
Cross-reactivities and specificities of the antibodies. Several lines of evidence in this paper point to the high specificities and low cross-reactivities of these antibodies to either rat NP-OT or rat NP-AVP (Figs. 4 to 7, 12, and 14) . We found, however, that whereas this was the case in liquid phase assays, the situation in solid phase assays (Fig. 8) was quite different. As is illustrated by the case of PS 41 versus PS 45 (cf. Figs. 5 and 8B), the higher the affinity constant of the antibody, the greater was its cross-reactivity found in the solid phase assay. PS 41, which is about 25 times lower in affinity than PS 45 (Table I) and is a poorer antibody for the liquid phase RIA of NP-AVP, is a superior antibody for use in solid phase assays because of its lower cross-reactivity to NP-OT (Fig. 8) .
We focused on this issue of cross-reactivity in solid phase assays because neurobiologists often use the same antibody reagents for both liquid phase RIA and immunocytochemical procedures. The immunocytochemical data we have presented (Figs. 9 and 10) clearly show that the antibodies used in this type of procedure are similar in their cross-reactivities to those found in solid phase biochemical assays (Fig. 8) and not liquid phase assays (Figs. 4 to 7) . In principle, immunocytochemistry represents an extreme form of the solid phase assay in that the antigen (e.g., NP) is present in the NSV at very high concentration (i.e., around 84,000 molecules/NSV; see Morris et al., 1978) . This effect of increased concentration in the solid phase for immunocytochemical assay as opposed to the liquid phase assay is expected on theoretical grounds (see Berzofsky and Berkower, 1984) , in part due to an increase in the apparent affinity of the bivalent antibody for the antigen under these conditions. The high local concentration of antigen in solid phase assays (especially in ICC of antigens present in highly concentrated form in the cell) also causes an increase in apparent affinity due to a "retention effect" (Silhavy et al., 1975) . Thus, even a monovalent antibody which has just detached from the substrate would have a higher probability of reassociating with an antigen molecule than of diffusing away from the substrate. As a consequence of the above, antibodies with modest liquid phase affinities can undergo essentially irreversible interactions with immobilized antigen in solid phase assays (Berzofsky and Berkower, 1984) . Hence, a small cross-reactiv- The discrepancy between liquid and solid phase affinities itation (see "Materials and Methods"). Note the absence of measurable presents an obvious difficulty for absorption controls in imcross-reactivity, relative to control antibody (HO-13-14, anti-Thy 1.1 munocytochemistry. It has been noted that including an excess monoclonal antibody).
of antigen in the primary antibody solution does not always (Sternberger, 1979) . That this may be the case, even for monoclonal antibodies, can be illustrated by considering the case of PS 45. PS 45 is an extraordinarily specific antibody for NP-AVP in liquid phase assays (Figs. 4 and 5) but cross-reacts strongly with NP-OT in solid phase assays (Fig.  8 ) and in immunocytochemistry (Figs. 9 and 10) . Given this information, it is apparent that a conventional absorption control procedure using NP-OT would not absorb PS 45 and, hence, would not prevent this antibody from cross-reacting with NP-OT-containing cells in immunocytochemical studies. In contrast, conventional absorption procedures using NP-AVP NP-AVP and NP-OT cells in immunocytochemical experiments. Therefore, these "controls".would lead to a completely incorrect conclusion, i.e., that the NP-OT cells contained NP-AVP! The inadequacy of absorption controls as criteria for proof for "molecular" identity or even "specific antigenic determinant" identity has also been demonstrated by Nigg et al. (1982) .
We wish to emphasize the point that, although monoclonal antibodies are extremely valuable tools for neurobiologists, the evidence that they react "specifically" with biological antigens in a particular assay cannot be used as evidence for molecular would completely eliminate this antibody's reaction with both identity (or even precursor relationships) in other assays, in 
